Evidence for the effectiveness of immunomodulatory drugs in MS is problematic because: - there are few good quality trials for each drug - trials often have methodological limitations or poor reporting of data - trials are often of small size and short duration - there is no consistency in treatment regimes, patient groups and outcome measures - the clinical significance of reported benefits is not clear.